- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Theralase Shares Latest Research at Photodynamic Association Meeting
Theralase Technologies released new research on phosphorescent photosensitizers was presented at this year’s International Photodynamic Association World Congress.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) released new research on phosphorescent photosensitizers was presented at this year’s International Photodynamic Association World Congress.
As quoted in the press release:
Angelika Rueck, Ph.D, University of Ulm, presented, “New phosphorescent Photo Sensitizers (“PS“) to follow up PDT response by Fluorescence Lifetime Imaging (“FLIM“) and PS Phosphorescence Lifetime Imaging (“PLIM“).”
Dr. Rueck presented how the Theralase patented PDC, TLD-1433, has demonstrated pre-clinically that:
- It is able to localize to the mitochondria of T-24 human bladder cancer cells and not the nucleus (Effective way to kill cancer cells without nuclear damage)
- Under simultaneous FLIM and PLIM activation the cell’s metabolism and oxygenation during PDT can be measured (By measuring oxygenation levels during PDT, the efficacy of PDT treatment can be optimized)
TLD-1433 PLIM and NADH FLIM can determine oxygenation and cellular metabolism during PDT and hence optimize efficacy of the treatment for various cancer cell types.
Angelika Ruelck, Ph.D., stated that, “FLIM/PLIM allows deep insight into the light induced mechanisms during PDT, allowing Theralase the opportunity to overcome the difficulty of treating under hypoxic (low oxygen) conditions or hypoxic tumour areas, common to cancer cells. The combination of PLIM with PDT treatment planning using TLD-1433, opens new avenues towards increasing patient outcomes during PDT treatment.”
Roger Dumoulin-White, President and CEO of Theralase, stated that, “Theralase is delighted that Dr. Rueck presented the latest research on phosphorescent photosensitizers to such a respected group of international researchers and clinicians at the 16th IPA World Congress. This research will allow Theralase the ability to successfully commercialize this next generation PDT technology for NMIBC and various other cancers.”
Click here to read the full press release.
Source: www.accesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.